The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CPHI | -11.54% | -99.35% | -63.4% | -100% |
| S&P | +16.49% | +84.25% | +12.99% | +507% |
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
No news articles found for China Pharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $756.22K | -31.3% |
| Gross Profit | -$257.61K | 58.7% |
| Gross Margin | -34.07% | 22.7% |
| Market Cap | $6.36M | -84.3% |
| Market Cap / Employee | $27.54K | 0.0% |
| Employees | 231 | -3.3% |
| Net Income | -$651.48K | 41.7% |
| EBITDA | -$272.12K | 29.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $267.63K | -62.8% |
| Accounts Receivable | $224.64K | -32.6% |
| Inventory | 1.7 | -33.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $128.26K | -91.0% |
| Short Term Debt | $3.44M | 33.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.66% | 11.3% |
| Return On Invested Capital | -48.05% | 26.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$237.60K | -529.7% |
| Operating Free Cash Flow | -$236.99K | -404.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.36 | 10.83 | 0.82 | 0.96 | -82.51% |
| Price to Sales | 1.37 | 2.00 | 1.33 | 1.86 | 152.76% |
| Price to Tangible Book Value | 19.17 | 69.63 | 10.07 | 31.51 | 134.23% |
| Price to Free Cash Flow TTM | 16.39 | 48.33 | - | ||
| Enterprise Value to EBITDA | -12.21 | -27.20 | -26.08 | -39.79 | 110.09% |
| Free Cash Flow Yield | 6.1% | 2.1% | - | ||
| Return on Equity | -61.6% | -59.1% | -52.0% | -42.5% | -43.43% |
| Total Debt | $3.59M | $3.51M | $3.43M | $3.57M | -11.04% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
